BRISTOL-MYERS SQUIBB COMPANY for BRISTOL-MYERS SQUIBB COMPANY
What was lobbied
8 issue areas, each in the filer's own words, with who lobbied on it and where.
Budget/Appropriations BUD
H.Con.Res 85, S.Con.Res 13, House and Senate Budget Resolutions. Lobbied to ensure safety and access to prescription drugs.
| Lobbyist | Covered position, as disclosed |
|---|---|
| MICHAEL CAROZZA | — |
| LANE PENRY | — |
| CHRISTOPHER PERNIE | — |
Consumer Issues/Safety/Products CSP
NO BILL, Bisphenol A (BPA). Lobbied Members of Congress regarding BPA in containers.
| Lobbyist | Covered position, as disclosed |
|---|---|
| MICHAEL CAROZZA | — |
Welfare WEL
NO BILL, WIC Program. Lobbied on reauthorization of WIC Program.
| Lobbyist | Covered position, as disclosed |
|---|---|
| MICHAEL CAROZZA | — |
Taxation/Internal Revenue Code TAX
NO BILL, Tax Reform. Lobbied to gather information on potential legislation regarding deferral of foreign income.
| Lobbyist | Covered position, as disclosed |
|---|---|
| MICHAEL CAROZZA | — |
| CHRISTOPHER PERNIE | — |
| RICHARD THOMPSON | — |
Copyright/Patent/Trademark CPT
S. 515 and H.R. 1260, Patent Reform Act of 2009. Lobbied Members of Congress to improve provisions related to inequitable conduct and damages. H.R. 1706, Protecting Consumer Access to Generic Drugs Act. Lobbied Members of Congress to protect access to safe and affordable prescription drugs. S. 369, Preserve Access to Affordable Generics Act. Lobbied Members of Congress to protect access to safe and affordable prescription drugs.
| Lobbyist | Covered position, as disclosed |
|---|---|
| LANE PENRY | — |
| CHRISTOPHER PERNIE | — |
| RICHARD THOMPSON | — |
Trade (domestic/foreign) TRD
Future of Trade Agreements. Lobbied in support of the pending Columbian and Korean FTAs. Implementation of discriminatory pricing decree regarding Turkey. Lobbied against pricing decree.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAVID E WARR | — |
Health Issues HCR
H. CON. RES 191, Continuing Resolution. Lobbied to ensure safety and access to prescription drugs. H.R. 3293, Labor Health and Human Services Appropriations bill. Lobbied to ensure safety and access to prescription drugs. NO BILL, Health Care Reform. Lobbied to gather information on potential legislation to improve the health care system and increase access to prescription drugs. H.R. 1548 and 1427/ S. 726, Biologics Price Competition & Innovation Act. Lobbied Members of Congress in support of an FDA pathway for biosimilar products, patient safety, and data exclusivity. S. 525, S. 1232 and H.R. 1298, Pharmaceutical Market Access and Drug Safety Act. Lobbied against passage of legislation to allow for the importation of unsafe prescription drugs. H.R.1, American Recovery and Reinvestment Act. Lobbied to include language encouraging clinical comparative effectiveness rather than cost effectiveness. H.R. 1105, making appropriations for Fiscal Year 2009. Lobbied for increased access to HIV/AIDS drugs in the Aids Drug Assistance Program. S. 982, Family Smoking Prevention and Tobacco Control Act. Lobbied against passage of legislation to allow for the importation of unsafe prescription drugs. S. 1213 and H.R. 2502, the Patient-Centered Outcomes Research Act. Lobbied Members of Congress to ensure safety and access to prescription drugs. H.R. 3293, Labor, HHS Appropriations Act. Lobbied Members of Congress to ensure safety and access to prescription drugs. H. Con. Res 191, Continuing Resolution. Lobbied Members of Congress to ensure safety and access to prescription drugs. H.R. 759, Food and Drug Administration Globalization Act of 2009. Lobbied to ensure safety and access to prescription drugs H.R. 1298/ S. 525/ S.1232, Pharmaceutical Market Access and Drug Safety Act of 2009. Lobbied to ensure safety and access to prescription drugs. Affordable Health Choices Act. Lobbied to ensure safety and access to prescription drugs. H.R. 2502, Comparative Effectiveness Research Act of 2009. Lobbied to ensure safety and access to prescription drugs. H.R. 3200/ S.1679/, Senate Finance Committee bill. Lobbied to improve the health care system and increase access to prescription drugs. H.R. 1427/ S. 726, Promoting Innovation and Access to Life-Saving Medicine Act. Lobbied Members of Congress in support of an FDA pathway for biosimilar products, patient safety and data exclusivity.
| Lobbyist | Covered position, as disclosed |
|---|---|
| MICHAEL CAROZZA | — |
| LANE PENRY | — |
| CHRISTOPHER PERNIE | — |
| SHAWN ZEDDIE TARRANT | — |
| RICHARD THOMPSON | — |
Medicare/Medicaid MMM
NO BILL, Medicare Part D Oversight. Lobbied Members of Congress to educate on the benefits of private negotiation in Medicare Part D. H.R.1458/ S.565, Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2007.Lobbied for passage of bills. S. 547, Drug Rebate Equalization Act of 2009. Lobbied against extending the Medicaid rebate to managed care organizations H.R.1458/ S.565, Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2007. Lobbied for passage of bills. H.R. 684/ S. 330, Medicare Prescription Drug Savings and Choice Act of 2009. Lobbied against establishing a government sponsored fall-back plan in Medicare Part D. H.R. 574/ S. 254, Medicare Home Infusion Therapy Coverage Act of 2009. Lobbied for passage of bills. S. 301, Physician Payments Sunshine Act of 2009. Lobbied to ensure access to prescription drugs. NO BILL, Medicare Part D Oversight. Lobbied Members of Congress to educate on the benefits of private negotiation in Medicare Part D. H.R. 1616, Early Treatment of HIV/AIDS. Lobbied in support of early treatment of HIV/AIDS.
| Lobbyist | Covered position, as disclosed |
|---|---|
| MICHAEL CAROZZA | — |
| LANE PENRY | — |
| CHRISTOPHER PERNIE | — |
| SHAWN ZEDDIE TARRANT | — |
| RICHARD THOMPSON | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.